XSTO
LIDDS
Market cap347kUSD
Feb 09, Last price
0.02SEK
Name
Lidds AB
Chart & Performance
P/E
—
P/S
104.91
EPS
—
Div Yield, %
—
Shrs. gr., 5y
39.85%
Rev. gr., 5y
12.92%
Revenues
32k
Net income
-6m
L-85.23%
CFO
-5m
L-79.28%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
LIDDS AB (publ), a pharmaceutical company headquartered in Uppsala, Sweden, specializes in the research, development, and marketing of therapeutic agents for cancer and various other medical conditions. The firm's innovative pipeline includes several drug candidates: NZ-2HOF is being advanced for prostate cancer; NZ-DTX targets a broad spectrum of malignancies such as breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX is in development for solid tumors; NZ-IO represents an immunotherapy; NZ-STING focuses on immuno-oncology; and NZ-TLR9 aims to bolster cancer immunotherapies. Additionally, LIDDS AB (publ) maintains a collaborative partnership with PharmIdea SIA, concentrating efforts on anti-cancer medications and the creation of sterile drug formulations.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||